Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7CLEZ)

Drug Name

Eltanexor oral Drug Info

Synonyms

KPT-8602; Eltanexor; UNII-Q59IQJ9NTK; Q59IQJ9NTK; 1642300-52-4; Eltanexor [INN]; Eltanexor [WHO-DD]; SCHEMBL16324809; MolPort-044-830-659; s8397; AKOS032945053; CS-5947; HY-100423; (E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide; 5-Pyrimidineacetamide, alpha-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)methylene)-, (alphaE)-; (2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1/2	[1]
Myelodysplastic syndrome	2A37	Phase 1/2	[1]
Prostate cancer	2C82.0	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 86345880
CAS Number: CAS 1642300-52-4
TTD Drug ID: DM7CLEZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Exportin-1 (XPO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selinexor	DMBD4K3	Multiple myeloma	2A83	Phase 3	[2]
Selinexor oral	DMDLOBZ	Recurrent glioblastoma	2A00.00	Phase 2	[3]
SL-801	DMIVGYK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
KOS-1815	DMCGFY6	Solid tumour/cancer	2A00-2F9Z	Preclinical	[2]
S109	DM2JYQA	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
Octahydrocurcumin	DMUFDR6	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Exportin-1 (XPO1)	TTCJUR4	XPO1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97.
5	Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38.